Semantic Scholar uses AI to extract papers important to this topic.
Abstract 1. Pradigastat is a potent and specific diacylglycerol acyltransferase-1 (DGAT1) inhibitor effective in lowering… Expand Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, has activity in common metabolic diseases associated with… Expand The DGAT1 inhibitor, pradigastat, demonstrated a mild phototoxicity signal in preclinical studies. Therefore, this clinical trial… Expand Pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, has been studied in familial chylomicronemia syndrome. To… Expand BackgroundFamilial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase (LPL) deficiency… Expand Pradigastat is a potent and selective inhibitor of diacylglycerol acyltransferase 1, an enzyme highly expressed in the small… Expand OBJECTIVE
An in vitro drugdrug interaction (DDI) study was performed to assess the potential for pradigastat to inhibit breast… Expand Background and ObjectivePradigastat, a novel diacylglycerol acyltransferase 1 inhibitor, is under development to treat familial… Expand Pradigastat, a novel diacylglycerol acyltransferase‐1 inhibitor, was evaluated for both pharmacokinetic (PK) and pharmacodynamic… Expand